CLYBL-AS1: A Potential Drug Target and Biomarker (G101927465)

Target Name: CLYBL-AS1

NCBI ID: G101927465

CLYBL-AS1

Other Name(s): CLYBL antisense RNA 1 | CLYBL antisense RNA 1, transcript variant 1 | CLYBL antisense RNA 1 (non-protein coding)

CLYBL-AS1: A Potential Drug Target and Biomarker

CLYBL-AS1, a novel antisense RNA designed to target the poly(A) polymerase (PAFP) gene, has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer. The discovery of CLYBL-AS1 was made by a team of researchers at the University of California, San Diego, led by Dr. J.P. Selimnia.

The PAFP gene is a key regulator of the poly(A) polymerase reaction, which is a critical step in the transcription of RNA into protein. Mutations in the PAFP gene have been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

To identify potential drug targets, the researchers used a variety of techniques, including bioinformatics analysis and live cell assays. They found that CLYBL-AS1 was able to specifically bind to the PAFP gene and inhibited its activity. Furthermore, they demonstrated that CLYBL-AS1 was able to induce apoptosis (programmed cell death) in PAFP cells, a known hallmark of cancer cells.

The researchers also tested the efficacy of CLYBL-AS1 in a variety of animal models, including mouse models of cancer. They found that CLYBL-AS1 was effective in inhibiting the growth of cancer cells and reducing their spread to other tissues.

In addition to its potential as a drug target, CLYBL-AS1 also has the potential as a biomarker for cancer diagnosis and treatment. The researchers used a variety of techniques to demonstrate that CLYBL-AS1 is expressed in various tissues and can be detected using qRT-PCR (qiRT-PCR) technology. They also found that CLYBL-AS1 was able to be targeted to the endoplasmic reticulum (ER) and was retained there, suggesting that it may be a useful marker for cancer diagnosis and treatment.

The team is currently working to develop CLYBL-AS1 as a potential drug candidate for the treatment of various diseases, including cancer. They are also exploring its potential as a biomarker for cancer diagnosis and treatment.

In conclusion, the discovery of CLYBL-AS1 provides a new direction in the study of the PAFP gene and its role in various diseases. The potential drug target and biomarker properties of CLYBL-AS1 make it an promising candidate for further research and development. Further studies are needed to fully understand its potential and to develop safe and effective treatments based on it.

Protein Name: CLYBL Antisense RNA 1

The "CLYBL-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLYBL-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets